Melanoma News and Research

Latest Melanoma News and Research

Data from Nivolumab phase I study in patients with kidney cancer to be presented at ASCO 2013

Researchers at Dartmouth-Hitchcock Norris Cotton Cancer Center will present a poster on a phase I clinical trial of Nivolumab, a PD-1 receptor blocking antibody, being used in combination with other drugs in patients with metastatic renal cell carcinoma at the ASCO Annual Meeting on June 3, 2013.

4 Jun 2013

Amgen reports encouraging results from talimogene laherparepvec phase 3 study in patients with metastatic melanoma

Amgen today announced detailed results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).

3 Jun 2013

New drug shows promising results with manageable side effects for treating melanoma

Researchers from UCLA's Jonsson Comprehensive Cancer Center report that a new drug in preliminary tests has shown promising results with very manageable side effects for treating patients with melanoma, the deadliest form of skin cancer.

3 Jun 2013

Combination of ipilimumab and nivolumab drugs reduces tumor size in metastatic melanoma patients

The combination of the immunotherapy drug ipilimumab and the investigational antibody drug nivolumab led to long-lasting tumor shrinkage in more than half of patients with metastatic melanoma, according to results from a Phase I trial simultaneously published online on Sunday, June 2, in The New England Journal of Medicine and presented by Memorial Sloan-Kettering Cancer Center researchers at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO).

3 Jun 2013

Lambrolizumab shows significant antitumor activity in patients with advanced melanoma

Researchers from UCLA's Jonsson Comprehensive Cancer Center led by Dr. Antoni Ribas, professor of medicine in the division of hematology-oncology, report preliminary results showing significant antitumor activity with very manageable side effects from a new drug being tested in patients with advanced melanoma, the deadliest form of skin cancer.

3 Jun 2013

Mount Sinai researchers present landmark studies at ASCO meeting

Icahn School of Medicine at Mount Sinai researchers will present several landmark studies at the 2013 American Society of Clinical Oncology meeting May 31-June 4, 2013 in Chicago, including data on the likelihood of spousal human papillomavirus oral infection, new gene signatures in melanoma, and issues with high readmission rates after cancer surgery.

3 Jun 2013

Selumetinib demonstrates clinical benefit for patients with metastatic uveal melanoma

The experimental drug selumetinib is the first targeted therapy to demonstrate significant clinical benefit for patients with metastatic uveal melanoma, according to new Memorial Sloan-Kettering Cancer Center research presented on Saturday, June 1, at the 49th annual meeting of the American Society of Clinical Oncology.

3 Jun 2013

New therapy for lung cancer produces manageable side effects

A promising new therapy for the most common form of lung cancer appears to produce largely manageable side effects, and an ongoing clinical trial is determining whether the compound treats tumors more effectively than what's on the market, according research that scientists at Fox Chase Cancer Center will present at the 49th Annual Meeting of the American Society of Clinical Oncology on Saturday, June 1.

1 Jun 2013

Nanoparticle-based immunotherapy for cancer

The German Research Foundation has established a new Collaborative Research Center on "Nanodimensional polymer therapeutics for tumor therapy" (CRC 1066) at Johannes Gutenberg University Mainz and the Max Planck Institute for Polymer Research (MPI-P).

1 Jun 2013

Oncothyreon, Array BioPharma to develop and commercialize ARRY-380 for breast cancer patients

Oncothyreon Inc. and Array BioPharma Inc. today announced that they will collaborate to develop and commercialize ARRY-380, an orally active, reversible and selective small-molecule HER2 inhibitor.

30 May 2013

Isaiah J. Fidler earns 2013 American Cancer Society Medal of Honor for Basic Research

When Isaiah J. Fidler, D.V.M., Ph.D., left his veterinary surgical practice to pursue a doctorate that would allow him to study and combat the lethal spread of cancer to other organs, he got lots of advice. The common message: Don't go there.

30 May 2013

Tafinlar, Mekinist get FDA approval to treat patients with advanced melanoma

The U.S. Food and Drug Administration today approved two new drugs, Tafinlar (dabrafenib) and Mekinist (trametinib), for patients with advanced (metastatic) or unresectable (cannot be removed by surgery) melanoma, the most dangerous type of skin cancer.

30 May 2013

EADV spring symposium: Bioalliance Pharma presents Sitavig study results

BioAlliance Pharma SA, a Company dedicated to the development of orphan oncology products and supportive care products, has presented the results of the pharmacokinetic and pharmacodynamic study on Sitavig at the 10th EADV spring symposium (European Academy of Dermatology and Venereology) in Cracow (Poland) on May 24, 2013.

28 May 2013

FDA gives Priority Review to Celgene's ABRAXANE sNDA for advanced pancreatic cancer

Celgene International Sàrl, a subsidiary of Celgene Corporation today announced that the U.S. Food and Drug Administration has assigned a Priority Review designation to the supplemental New Drug Application for the use of ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine for the first-line treatment of patients with advanced pancreatic cancer.

23 May 2013

National Council urges consumers to select sunscreen products that offer broad spectrum protection

As millions of Americans prepare to enjoy the great outdoors this Memorial Day weekend, the National Council on Skin Cancer Prevention has designated the Friday before Memorial Day, May 24, 2013, as "Don't Fry Day" to raise awareness of the importance of practicing sun-safe behaviors.

23 May 2013

Study shows PDH enzyme plays a major role in regulation of oncogene-induced cellular senescence

An article published on the journal Nature describes the major role that Pyruvate dehydrogenase (PDH) —an enzyme of cellular energy metabolism— plays in the regulation of the cellular senescence induced by the oncogene BRAF, which usually appears mutated in melanoma and other cancers.

22 May 2013

IBD patients are at higher risk of melanoma, report researchers

Patients with inflammatory bowel disease (IBD) are at higher risk of melanoma, a form of skin cancer, report researchers at Mayo Clinic. Researchers found that IBD is associated with a 37 percent greater risk for the disease. The findings were presented at the Digestive Disease Week 2013 conference in Orlando, Fla.

21 May 2013

Exposure to sun of increases risk of cutaneous melanoma among young Israeli children

A new study conducted using extensive medical records of over one million Israeli adolescents before military service shows clearly how exposure to the Israeli sun of young, light-skinned children increases substantially the risk of cutaneous melanoma (a serious form of skin cancer).

20 May 2013

Study provides strong hook for off-the-news feature on adolescent girls and risks of tanning

Prom season and summer approach, and with them teenage girls seeking suntans. New research published in the May issue of Pediatrics finds that the number of children diagnosed with melanoma has increased an average 2% a year since the 1970s, with the incidence of melanoma significantly higher among white girls, age 15-19, than among boys and younger children.

20 May 2013

Neupro reduces PLMS and total NSBP elevations in patients with RLS, study finds

UCB today announced data from a double-blind, placebo-controlled study that found that Neupro (Rotigotine Transdermal System) reduced total nocturnal systolic blood pressure elevations associated with periodic limb movements during sleep and total PLMS in patients with idiopathic moderate-to-severe Restless Legs Syndrome/Willis-Ekbom disease.

18 May 2013

Melanoma News and Research

Latest Melanoma News and Research

Data from Nivolumab phase I study in patients with kidney cancer to be presented at ASCO 2013

Amgen reports encouraging results from talimogene laherparepvec phase 3 study in patients with metastatic melanoma

New drug shows promising results with manageable side effects for treating melanoma

Combination of ipilimumab and nivolumab drugs reduces tumor size in metastatic melanoma patients

Lambrolizumab shows significant antitumor activity in patients with advanced melanoma

Mount Sinai researchers present landmark studies at ASCO meeting

Selumetinib demonstrates clinical benefit for patients with metastatic uveal melanoma

New therapy for lung cancer produces manageable side effects

Nanoparticle-based immunotherapy for cancer

Oncothyreon, Array BioPharma to develop and commercialize ARRY-380 for breast cancer patients

Isaiah J. Fidler earns 2013 American Cancer Society Medal of Honor for Basic Research

Tafinlar, Mekinist get FDA approval to treat patients with advanced melanoma

EADV spring symposium: Bioalliance Pharma presents Sitavig study results

FDA gives Priority Review to Celgene's ABRAXANE sNDA for advanced pancreatic cancer

National Council urges consumers to select sunscreen products that offer broad spectrum protection

Study shows PDH enzyme plays a major role in regulation of oncogene-induced cellular senescence

IBD patients are at higher risk of melanoma, report researchers

Exposure to sun of increases risk of cutaneous melanoma among young Israeli children

Study provides strong hook for off-the-news feature on adolescent girls and risks of tanning

Neupro reduces PLMS and total NSBP elevations in patients with RLS, study finds

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Melanoma News and Research

Latest Melanoma News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in